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A recent study1 reports the asso-
ciation between polymorphisms of
genes regulating plasma gamma-gluta-
myltransferase (GGT) activity and the
risk of diabetes, cardiovascular, and
other diseases, including inﬂammatory
bowel disease (IBD). As remarked by
the authors, the function of GGT is to
make cysteine available for the synthe-
sis of intracellular glutathione, thus a
decrease in GGT gene expression may
lead to decreased glutathione availabil-
ity and may impair the efﬁciency of
antioxidant defenses; this interpretation
is in contrast with the fact that, in the
case of diabetes and coronary athero-
sclerosis, the diseases are associated
with increased values of plasma GGT
rather than decreased values,2 and no
disease has yet been associated with
decreased levels of plasma GGT. In
IBD a decrease in GGT activity in the
inﬂamed intestinal mucosa has been
reported,3 but a correlation between
plasma GGT levels and IBD has never
been found.
To check whether this might
depend on the modest sensitivity and
reproducibility of the current clinical
assay for GGT, we analyzed plasma
samples from a small cohort of 48 sub-
jects with IBD (27 Crohn’s disease and
21 ulcerative colitis) and 48 healthy
subjects, matched for age and gender
(Table 1). When the samples were
assayed by the current routine clinical
laboratory procedure, based on the hy-
drolysis of the chromogen gamma-glu-
tamyl-3-carboxy-4-nitroanilide,4 we did
not ﬁnd any difference between IBD
patients and controls.
We then repeated the analysis
with a high sensitivity ﬂuorescent
assay,5 which allows the separate
determination of the four GGT fractions
present in human blood: b-GGT (molec-
ular weight [MW] 2000 kDa), m-GGT,
(MW 1000 kDa), s-GGT (MW 140
kDa), and f-GGT (MW 70 kDa).
By this method we found that two
of the four fractions, m-GGT and
f-GGT, were signiﬁcantly reduced in
IBD as compared with controls (Table 1).
Within the group with IBD, no correla-
tion emerged by Pearson’s correlation
analysis between the values of these frac-
tions and the levels of fecal calprotectin,
C-reactive protein (CRP), erythrocyte
sedimentation rate, or therapy, thus sug-
gesting that reduced m-GGT and f-GGT
are a trait of the disease, and not a conse-
quence of its clinical activity.
To our knowledge, this is the
ﬁrst report concerning the association
between low plasma GGT activity and
IBD, conﬁrming the results of the
study by Middelberg et al,1 and the
ﬁrst associating a human disease with
decreased values of GGT, rather than
increased values. The low sensitivity
of the routine clinical assay for GGT
seems to impair its diagnostic value
and needs to be overcome, possibly
opening new perspectives for the study
of the many diseases associated with
polymorphisms regulating GGT expres-
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TABLE 1. Characteristics of Subjects with Inﬂammatory Bowel Disease (IBD).
Controls (n¼48) IBD (n¼48)
P Controls
vs. IBD
Males, n 31 31
Age, years 35.0 (28.0–48.5) 35.5 (26.5–48.5) n.s.
Calprotectin, lg/g N.A. 224.5 (81.5–423.5)
CRP, mg/L 0.08 (0.04–0.14) 1.04 (0.40–4.31) < 0.05
ESR 1h, mm/h N.A. 16.0 (8.0–31.0)
Total GGT, U/L * 18.3 (13.3–24.8) 14.9 (11.1–21.0) n.s.
b-GGT, U/L * 1.4 (0.9–2.4) 1.7 (0.9–2.8) n.s.
m-GGT, U/L * 0.5 (0.3–0.9) 0.2 (0.1–0.4) < 0.0001
s-GGT, U/L * 5.4 (2.8–8.8) 3.9 (2.6–7.6) n.s.
f-GGT, U/L 10.0 (8.3–13.5) 8.4 (6.2–10.5) < 0.01
Data presented are median (25th-75th percentile). CRP, C-reactive protein; ESR, erythrocyte sedi-
mentation rate; GGT, gamma-glutamyltransferase. Statistical analysis: Student’s t-test; *statistical
analysis performed on ln-transformed data. n.s., not signiﬁcant; N.A., not available.
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